Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570961 | 1.00 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3378213 | 1.00 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1162230 | 0.95 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL27604122 | 0.95 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL16339563 | 0.94 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL16339562 | 0.94 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3783892 | 0.90 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL2062991 | 0.90 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL2062994 | 0.90 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL6837916 | 0.90 | CTSK (0.56) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111954539-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4218785-A2 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-3723783-B1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-111954539-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3723783-A1 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118878-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2019-06-20 | — | — | WO | disclosed |
| US-8217050-B2 | Adenine derivative as inhibitors of HSP90 for the treatment of cancer | CHROMA THERAPEUTICS LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-20100035901-A1 | ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. | 2010-02-11 | — | — | US | disclosed |
| CN-101541800-A | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer | CHROMA THERAPEUTICS LTD (GB) | 2009-09-23 | — | — | CN | disclosed |
| EP-2084161-A1 | ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008056120-A1 | ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795196-B2 | Mitochondria-targeting peptides | HSPE1, TFAM, TNNI3 | CTSK 909/4885CTSS 1818/4885MEN1 4795/4885 |
| US-20100035901-A1 | ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | HSP90AA1, HSP90AB1, HSP90B1 | CTSK 4422/4885CTSS 4530/4885MEN1 4107/4885 |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | CTSK 909/4885CTSS 1818/4885MEN1 4795/4885 |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | CTSK 909/4885CTSS 1818/4885MEN1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.